> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# State Street Holds 4.5% Of 4D Molecular Therapeutics Without Seeking Control
- URL: https://www.bullished.co/state-street-holds-4-5-of-4d-molecular-therapeutics-without-seeking-control-c7de3080/
- Published: 2026-11-10T12:27:36.000Z
- Updated: 2026-11-10T12:27:36.000Z
- Description: The institutional holder reported 2,469,425 common shares in a disclosure covering September 30, 2026.
- Author: Matteo Parrino
- Tags: SEC Filings, FDMT, Industry: Healthcare

State Street reported a [4.5% stake](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000602/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) in [4D Molecular Therapeutics](https://www.bullished.co/tag/fdmt/), which develops genetic medicines, in a passive ownership disclosure filed Tuesday. The holding covered 2,469,425 common shares as of September 30, 2026, and State Street certified that it was not seeking to change or influence the company's control.

## Shared Authority Over The Holding

State Street reported [shared voting authority](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000602/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) for 2,416,070 shares and shared power to dispose of all 2,469,425 shares. It reported no sole voting or disposal authority.

The securities were bought and held as part of routine business, State Street certified. The disclosure also named SSGA Funds Management, State Street Global Advisors Europe and State Street Global Advisors Trust Company.

## Retina And Lung Medicines In Development

4D Molecular Therapeutics has no marketed products. Its business centers on engineered adeno-associated viruses—viral carriers used to deliver genetic medicines—with programs targeting the retina and lungs, according to its annual report for the fiscal year ended December 31, 2025.

Its lead candidate, 4D-150, is in late-stage trials for wet age-related macular degeneration, and the company plans a late-stage trial for diabetic macular edema. The cystic fibrosis candidate 4D-710 is in a mid-stage trial supported by funding and collaboration from the Cystic Fibrosis Foundation.

The company is also developing 4D-725 for alpha-1 antitrypsin deficiency lung disease at the preclinical stage. Its discovery platform selects viral carriers in non-human primates to target particular tissues; it produces those carriers internally and through contract manufacturers.

FDMT's market value was $689 million as of 7:22 a.m. ET Tuesday.

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [SCHEDULE 13G — STATE STREET CORPORATION re: 4D MOLECULAR THERAPEUTICS INC (FDMT)](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000602/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR

### More on 4D Molecular Therapeutics

- [4D Molecular Therapeutics Starts Late-Stage DME Trial As Two-Year Data Show 61% Injection Reduction](https://www.bullished.co/4d-molecular-therapeutics-starts-late-stage-dme-trial-as-two-year-data-show-61-injection-11e39b95/)

[All 4D Molecular Therapeutics (FDMT) coverage →](https://www.bullished.co/tag/fdmt/)